261 related articles for article (PubMed ID: 28350808)
61. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
[TBL] [Abstract][Full Text] [Related]
62. Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies.
Dasari S; Theis JD; Vrana JA; Meureta OM; Quint PS; Muppa P; Zenka RM; Tschumper RC; Jelinek DF; Davila JI; Sarangi V; Kurtin PJ; Dogan A
J Proteome Res; 2015 Apr; 14(4):1957-67. PubMed ID: 25734799
[TBL] [Abstract][Full Text] [Related]
63. In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells.
Arosio P; Owczarz M; Müller-Späth T; Rognoni P; Beeg M; Wu H; Salmona M; Morbidelli M
PLoS One; 2012; 7(3):e33372. PubMed ID: 22432016
[TBL] [Abstract][Full Text] [Related]
64. Analysis of plasma cell clonality in localized AL amyloidosis.
Setoguchi M; Hoshii Y; Kawano H; Ishihara T
Amyloid; 2000 Mar; 7(1):41-5. PubMed ID: 10842704
[TBL] [Abstract][Full Text] [Related]
65. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
Morgan GJ
Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
[TBL] [Abstract][Full Text] [Related]
66. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
[TBL] [Abstract][Full Text] [Related]
67. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains.
Connors LH; Jiang Y; Budnik M; Théberge R; Prokaeva T; Bodi KL; Seldin DC; Costello CE; Skinner M
Biochemistry; 2007 Dec; 46(49):14259-71. PubMed ID: 18004879
[TBL] [Abstract][Full Text] [Related]
68. Contribution of human smooth muscle cells to amyloid angiopathy in AL (light-chain) amyloidosis.
Vora M; Kevil CG; Herrera GA
Ultrastruct Pathol; 2017; 41(5):358-368. PubMed ID: 28796568
[TBL] [Abstract][Full Text] [Related]
69. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
Marin-Argany M; Lin Y; Misra P; Williams A; Wall JS; Howell KG; Elsbernd LR; McClure M; Ramirez-Alvarado M
J Biol Chem; 2016 Sep; 291(38):19813-25. PubMed ID: 27462073
[TBL] [Abstract][Full Text] [Related]
70. Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains.
Kim YS; Cape SP; Chi E; Raffen R; Wilkins-Stevens P; Stevens FJ; Manning MC; Randolph TW; Solomon A; Carpenter JF
J Biol Chem; 2001 Jan; 276(2):1626-33. PubMed ID: 11050093
[TBL] [Abstract][Full Text] [Related]
71. Nodular pulmonary immunoglobulin light chain deposits with coexistent amyloid and nonamyloid features in an HIV-infected patient.
Stokes MB; Jagirdar J; Burchstin O; Kornacki S; Kumar A; Gallo G
Mod Pathol; 1997 Oct; 10(10):1059-65. PubMed ID: 9346188
[TBL] [Abstract][Full Text] [Related]
72. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis.
Buxbaum JN; Chuba JV; Hellman GC; Solomon A; Gallo GR
Ann Intern Med; 1990 Mar; 112(6):455-64. PubMed ID: 2106817
[TBL] [Abstract][Full Text] [Related]
73. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
Nevone A; Girelli M; Mangiacavalli S; Paiva B; Milani P; Cascino P; Piscitelli M; Speranzini V; Cartia CS; Benvenuti P; Goicoechea I; Fazio F; Basset M; Foli A; Nanci M; Mazzini G; Caminito S; Sesta MA; Casarini S; Rognoni P; Lavatelli F; Petrucci MT; Olimpieri PP; Ricagno S; Arcaini L; Merlini G; Palladini G; Nuvolone M
Leukemia; 2022 Aug; 36(8):2076-2085. PubMed ID: 35610346
[TBL] [Abstract][Full Text] [Related]
74. Thermal stability threshold for amyloid formation in light chain amyloidosis.
Poshusta TL; Katoh N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M
Int J Mol Sci; 2013 Nov; 14(11):22604-17. PubMed ID: 24248061
[TBL] [Abstract][Full Text] [Related]
75. Thermodynamic and fibril formation studies of full length immunoglobulin light chain AL-09 and its germline protein using scan rate dependent thermal unfolding.
Blancas-Mejía LM; Horn TJ; Marin-Argany M; Auton M; Tischer A; Ramirez-Alvarado M
Biophys Chem; 2015 Dec; 207():13-20. PubMed ID: 26263488
[TBL] [Abstract][Full Text] [Related]
76. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
77. Crystalline light-chain deposition and amyloidosis in the thyroid gland and kidneys of a patient with myeloma.
Hirota S; Miyamoto M; Kasugai T; Kitamura Y; Morimura Y
Arch Pathol Lab Med; 1990 Apr; 114(4):429-31. PubMed ID: 2108650
[TBL] [Abstract][Full Text] [Related]
78. Exploring the sequence features determining amyloidosis in human antibody light chains.
Rawat P; Prabakaran R; Kumar S; Gromiha MM
Sci Rep; 2021 Jul; 11(1):13785. PubMed ID: 34215782
[TBL] [Abstract][Full Text] [Related]
79. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
80. Recent advances in the management of AL Amyloidosis.
Kastritis E; Dimopoulos MA
Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
